Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| DEXCOM INCDXCM · Entity 3114 | EVP Chief Commercial Officer | March 23, 2021 | March 25, 2021 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
DEXCOM INC
Report date March 23, 2021 · Filed March 25, 2021
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Indirectby Trust | 6,654 |
Last balance in matching sequence
After 2021-03-23 transaction · row 5
Source-order balances reconcile. Account continuity and personal attribution are not independently verified.
5 source rowsRow 1 · 2021-03-23 · Sale · Disposed 18 · Balance 7,745 F1: On June 15, 2020, Mr. Doubleday adopted a 10b5-1 Plan. This 10b5-1 Plan allows the orderly disposition of shares owned by Mr. Doubleday. The shares set forth above were sold pursuant to the 10b5-1 Plan. F2: Shares are held by the Doubleday Living Trust U/A/D 5/26/2015, with respect to which the reporting person is a trustee. Row 2 · 2021-03-23 · Sale · Disposed 74 · Balance 7,671 F1: On June 15, 2020, Mr. Doubleday adopted a 10b5-1 Plan. This 10b5-1 Plan allows the orderly disposition of shares owned by Mr. Doubleday. The shares set forth above were sold pursuant to the 10b5-1 Plan. F2: Shares are held by the Doubleday Living Trust U/A/D 5/26/2015, with respect to which the reporting person is a trustee. Row 3 · 2021-03-23 · Sale · Disposed 655 · Balance 7,016 F1: On June 15, 2020, Mr. Doubleday adopted a 10b5-1 Plan. This 10b5-1 Plan allows the orderly disposition of shares owned by Mr. Doubleday. The shares set forth above were sold pursuant to the 10b5-1 Plan. F3: This transaction was executed in multiple trades at prices ranging from $359.70 to $360.67. The price above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transactions were effected. F2: Shares are held by the Doubleday Living Trust U/A/D 5/26/2015, with respect to which the reporting person is a trustee. Row 4 · 2021-03-23 · Sale · Disposed 268 · Balance 6,748 F1: On June 15, 2020, Mr. Doubleday adopted a 10b5-1 Plan. This 10b5-1 Plan allows the orderly disposition of shares owned by Mr. Doubleday. The shares set forth above were sold pursuant to the 10b5-1 Plan. F4: This transaction was executed in multiple trades at prices ranging from $360.94 to $361.83. The price above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transactions were effected. F2: Shares are held by the Doubleday Living Trust U/A/D 5/26/2015, with respect to which the reporting person is a trustee. Row 5 · 2021-03-23 · Sale · Disposed 94 · Balance 6,654 F1: On June 15, 2020, Mr. Doubleday adopted a 10b5-1 Plan. This 10b5-1 Plan allows the orderly disposition of shares owned by Mr. Doubleday. The shares set forth above were sold pursuant to the 10b5-1 Plan. F2: Shares are held by the Doubleday Living Trust U/A/D 5/26/2015, with respect to which the reporting person is a trustee. |
| Common StockSEC Table I · non-derivative | Direct | 21,554 |
Reported balance
Holding disclosure · report date 2021-03-23 · row 6
Holding and transaction disclosures are not merged.
1 source rowRow 6 · Balance 21,554 |
Filing footnotes · ownership attribution and instrument terms
F1: On June 15, 2020, Mr. Doubleday adopted a 10b5-1 Plan. This 10b5-1 Plan allows the orderly disposition of shares owned by Mr. Doubleday. The shares set forth above were sold pursuant to the 10b5-1 Plan.
F2: Shares are held by the Doubleday Living Trust U/A/D 5/26/2015, with respect to which the reporting person is a trustee.
F3: This transaction was executed in multiple trades at prices ranging from $359.70 to $360.67. The price above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transactions were effected.
F4: This transaction was executed in multiple trades at prices ranging from $360.94 to $361.83. The price above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transactions were effected.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| March 23, 2021 Filed Mar 25, 2021 00:18 UTC | DEXCOM INC DXCM · Entity 3114 | SaleCommon Stock | 94 | $362.45 | $34,070.30 |
DisclosureSEC source: 0001093557-21-000092 · edgardoc.xml · nonDerivative · entry 5 DOUBLEDAY RICHARD · CIK 0001466545 · EVP Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Indirect · by Trust Disclosed balance after: 6,654 F1 · shares: On June 15, 2020, Mr. Doubleday adopted a 10b5-1 Plan. This 10b5-1 Plan allows the orderly disposition of shares owned by Mr. Doubleday. The shares set forth above were sold pursuant to the 10b5-1 Plan. F2 · ownership.nature: Shares are held by the Doubleday Living Trust U/A/D 5/26/2015, with respect to which the reporting person is a trustee. Read SEC document |
| March 23, 2021 Filed Mar 25, 2021 00:18 UTC | DEXCOM INC DXCM · Entity 3114 | SaleCommon Stock | 268 | $361.37 | $96,846.70 |
DisclosureSEC source: 0001093557-21-000092 · edgardoc.xml · nonDerivative · entry 4 DOUBLEDAY RICHARD · CIK 0001466545 · EVP Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Indirect · by Trust Disclosed balance after: 6,748 F1 · shares: On June 15, 2020, Mr. Doubleday adopted a 10b5-1 Plan. This 10b5-1 Plan allows the orderly disposition of shares owned by Mr. Doubleday. The shares set forth above were sold pursuant to the 10b5-1 Plan. F4 · price: This transaction was executed in multiple trades at prices ranging from $360.94 to $361.83. The price above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transactions were effected. F2 · ownership.nature: Shares are held by the Doubleday Living Trust U/A/D 5/26/2015, with respect to which the reporting person is a trustee. Read SEC document |
| March 23, 2021 Filed Mar 25, 2021 00:18 UTC | DEXCOM INC DXCM · Entity 3114 | SaleCommon Stock | 655 | $360.33 | $236,017.66 |
DisclosureSEC source: 0001093557-21-000092 · edgardoc.xml · nonDerivative · entry 3 DOUBLEDAY RICHARD · CIK 0001466545 · EVP Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Indirect · by Trust Disclosed balance after: 7,016 F1 · shares: On June 15, 2020, Mr. Doubleday adopted a 10b5-1 Plan. This 10b5-1 Plan allows the orderly disposition of shares owned by Mr. Doubleday. The shares set forth above were sold pursuant to the 10b5-1 Plan. F3 · price: This transaction was executed in multiple trades at prices ranging from $359.70 to $360.67. The price above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transactions were effected. F2 · ownership.nature: Shares are held by the Doubleday Living Trust U/A/D 5/26/2015, with respect to which the reporting person is a trustee. Read SEC document |
| March 23, 2021 Filed Mar 25, 2021 00:18 UTC | DEXCOM INC DXCM · Entity 3114 | SaleCommon Stock | 74 | $358.13 | $26,501.62 |
DisclosureSEC source: 0001093557-21-000092 · edgardoc.xml · nonDerivative · entry 2 DOUBLEDAY RICHARD · CIK 0001466545 · EVP Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Indirect · by Trust Disclosed balance after: 7,671 F1 · shares: On June 15, 2020, Mr. Doubleday adopted a 10b5-1 Plan. This 10b5-1 Plan allows the orderly disposition of shares owned by Mr. Doubleday. The shares set forth above were sold pursuant to the 10b5-1 Plan. F2 · ownership.nature: Shares are held by the Doubleday Living Trust U/A/D 5/26/2015, with respect to which the reporting person is a trustee. Read SEC document |
| March 23, 2021 Filed Mar 25, 2021 00:18 UTC | DEXCOM INC DXCM · Entity 3114 | SaleCommon Stock | 18 | $352.88 | $6,351.84 |
DisclosureSEC source: 0001093557-21-000092 · edgardoc.xml · nonDerivative · entry 1 DOUBLEDAY RICHARD · CIK 0001466545 · EVP Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Indirect · by Trust Disclosed balance after: 7,745 F1 · shares: On June 15, 2020, Mr. Doubleday adopted a 10b5-1 Plan. This 10b5-1 Plan allows the orderly disposition of shares owned by Mr. Doubleday. The shares set forth above were sold pursuant to the 10b5-1 Plan. F2 · ownership.nature: Shares are held by the Doubleday Living Trust U/A/D 5/26/2015, with respect to which the reporting person is a trustee. Read SEC document |
| February 24, 2021 Filed Feb 26, 2021 23:01 UTC | DEXCOM INC DXCM · Entity 3114 | SaleCommon Stock | 1,110 | $404.00 | $448,440.00 |
DisclosureSEC source: 0001093557-21-000033 · edgardoc.xml · nonDerivative · entry 1 DOUBLEDAY RICHARD · CIK 0001466545 · EVP Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Indirect · by Trust Disclosed balance after: 7,763 F1 · shares: On June 15, 2020, Mr. Doubleday adopted a 10b5-1 Plan. This 10b5-1 Plan allows the orderly disposition of shares owned by Mr. Doubleday. The shares set forth above were sold pursuant to the 10b5-1 Plan. F2 · ownership.nature: Shares are held by the Doubleday Living Trust U/A/D 5/26/2015, with respect to which the reporting person is a trustee. Read SEC document |
| January 22, 2021 Filed Jan 26, 2021 01:21 UTC | DEXCOM INC DXCM · Entity 3114 | SaleCommon Stock | 11 | $371.98 | $4,091.83 |
DisclosureSEC source: 0001093557-21-000011 · edgardoc.xml · nonDerivative · entry 5 DOUBLEDAY RICHARD · CIK 0001466545 · EVP Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Indirect · by Trust Disclosed balance after: 8,873 F1 · shares: On June 15, 2020, Mr. Doubleday adopted a 10b5-1 Plan. This 10b5-1 Plan allows the orderly disposition of shares owned by Mr. Doubleday. The shares set forth above were sold pursuant to the 10b5-1 Plan. F7 · price: This transaction was executed in multiple trades at prices ranging from $371.675 to $372.015. The price above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transactions were effected. F3 · ownership.nature: Shares are held by the Doubleday Living Trust U/A/D 5/26/2015, with respect to which the reporting person is a trustee. Read SEC document |
| January 22, 2021 Filed Jan 26, 2021 01:21 UTC | DEXCOM INC DXCM · Entity 3114 | SaleCommon Stock | 310 | $370.24 | $114,775.58 |
DisclosureSEC source: 0001093557-21-000011 · edgardoc.xml · nonDerivative · entry 4 DOUBLEDAY RICHARD · CIK 0001466545 · EVP Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Indirect · by Trust Disclosed balance after: 8,884 F1 · shares: On June 15, 2020, Mr. Doubleday adopted a 10b5-1 Plan. This 10b5-1 Plan allows the orderly disposition of shares owned by Mr. Doubleday. The shares set forth above were sold pursuant to the 10b5-1 Plan. F6 · price: This transaction was executed in multiple trades at prices ranging from $370.240 to $370.595. The price above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transactions were effected. F3 · ownership.nature: Shares are held by the Doubleday Living Trust U/A/D 5/26/2015, with respect to which the reporting person is a trustee. Read SEC document |
| January 22, 2021 Filed Jan 26, 2021 01:21 UTC | DEXCOM INC DXCM · Entity 3114 | SaleCommon Stock | 254 | $369.31 | $93,803.85 |
DisclosureSEC source: 0001093557-21-000011 · edgardoc.xml · nonDerivative · entry 3 DOUBLEDAY RICHARD · CIK 0001466545 · EVP Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Indirect · by Trust Disclosed balance after: 9,194 F1 · shares: On June 15, 2020, Mr. Doubleday adopted a 10b5-1 Plan. This 10b5-1 Plan allows the orderly disposition of shares owned by Mr. Doubleday. The shares set forth above were sold pursuant to the 10b5-1 Plan. F5 · price: This transaction was executed in multiple trades at prices ranging from $369.16 to $369.82. The price above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transactions were effected. F3 · ownership.nature: Shares are held by the Doubleday Living Trust U/A/D 5/26/2015, with respect to which the reporting person is a trustee. Read SEC document |
| January 22, 2021 Filed Jan 26, 2021 01:21 UTC | DEXCOM INC DXCM · Entity 3114 | SaleCommon Stock | 169 | $368.20 | $62,226.15 |
DisclosureSEC source: 0001093557-21-000011 · edgardoc.xml · nonDerivative · entry 2 DOUBLEDAY RICHARD · CIK 0001466545 · EVP Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Indirect · by Trust Disclosed balance after: 9,448 F1 · shares: On June 15, 2020, Mr. Doubleday adopted a 10b5-1 Plan. This 10b5-1 Plan allows the orderly disposition of shares owned by Mr. Doubleday. The shares set forth above were sold pursuant to the 10b5-1 Plan. F4 · price: This transaction was executed in multiple trades at prices ranging from $367.90 to $368.49. The price above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transactions were effected. F3 · ownership.nature: Shares are held by the Doubleday Living Trust U/A/D 5/26/2015, with respect to which the reporting person is a trustee. Read SEC document |
| January 22, 2021 Filed Jan 26, 2021 01:21 UTC | DEXCOM INC DXCM · Entity 3114 | SaleCommon Stock | 366 | $367.51 | $134,509.83 |
DisclosureSEC source: 0001093557-21-000011 · edgardoc.xml · nonDerivative · entry 1 DOUBLEDAY RICHARD · CIK 0001466545 · EVP Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Indirect · by Trust Disclosed balance after: 9,617 F1 · shares: On June 15, 2020, Mr. Doubleday adopted a 10b5-1 Plan. This 10b5-1 Plan allows the orderly disposition of shares owned by Mr. Doubleday. The shares set forth above were sold pursuant to the 10b5-1 Plan. F2 · price: This transaction was executed in multiple trades at prices ranging from $366.87 to $367.66. The price above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transactions were effected. F3 · ownership.nature: Shares are held by the Doubleday Living Trust U/A/D 5/26/2015, with respect to which the reporting person is a trustee. Read SEC document |
| January 04, 2021 Filed Jan 6, 2021 22:10 UTC | DEXCOM INC DXCM · Entity 3114 | SaleCommon Stock | 10,970 | $366.07 | $4,015,787.90 |
DisclosureSEC source: 0001093557-21-000002 · edgardoc.xml · nonDerivative · entry 4 DOUBLEDAY RICHARD · CIK 0001466545 · EVP Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 21,524 F3 · shares: Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of RSUs. This sale is mandated by the Issuer's election under its equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the reporting person. F2 · balance_after: Included in this number are 3,916 unvested restricted stock units that will be forfeited to the Company on April 1, 2021 in accordance with Mr. Doubleday's Transition & Consulting Agreement. Read SEC document |
| January 04, 2021 Filed Jan 6, 2021 22:10 UTC | DEXCOM INC DXCM · Entity 3114 | SaleCommon Stock | 28 | $365.16 | $10,224.37 |
DisclosureSEC source: 0001093557-21-000002 · edgardoc.xml · nonDerivative · entry 3 DOUBLEDAY RICHARD · CIK 0001466545 · EVP Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 32,494 F3 · shares: Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of RSUs. This sale is mandated by the Issuer's election under its equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the reporting person. F5 · price: This transaction was executed in multiple trades at prices ranging from $365.0432 to $365.1871. The price above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transactions were effected. F2 · balance_after: Included in this number are 3,916 unvested restricted stock units that will be forfeited to the Company on April 1, 2021 in accordance with Mr. Doubleday's Transition & Consulting Agreement. Read SEC document |
| January 04, 2021 Filed Jan 6, 2021 22:10 UTC | DEXCOM INC DXCM · Entity 3114 | SaleCommon Stock | 27 | $362.96 | $9,800.01 |
DisclosureSEC source: 0001093557-21-000002 · edgardoc.xml · nonDerivative · entry 2 DOUBLEDAY RICHARD · CIK 0001466545 · EVP Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 32,522 F3 · shares: Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of RSUs. This sale is mandated by the Issuer's election under its equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the reporting person. F4 · price: This transaction was executed in multiple trades at prices ranging from $362.84 to $363.0623. The price above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transactions were effected. F2 · balance_after: Included in this number are 3,916 unvested restricted stock units that will be forfeited to the Company on April 1, 2021 in accordance with Mr. Doubleday's Transition & Consulting Agreement. Read SEC document |
| December 29, 2020 Filed Jan 6, 2021 22:10 UTC | DEXCOM INC DXCM · Entity 3114 | GiftCommon Stock | 950 | $0.00 | $0.00 |
DisclosureSEC source: 0001093557-21-000002 · edgardoc.xml · nonDerivative · entry 1 DOUBLEDAY RICHARD · CIK 0001466545 · EVP Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 32,549 F1 · shares: The transaction represents a gift by the Reporting Person of 950 shares to a charitable donor advised fund. F2 · balance_after: Included in this number are 3,916 unvested restricted stock units that will be forfeited to the Company on April 1, 2021 in accordance with Mr. Doubleday's Transition & Consulting Agreement. Read SEC document |
| December 23, 2020 Filed Dec 28, 2020 22:43 UTC | DEXCOM INC DXCM · Entity 3114 | SaleCommon Stock | 80 | $364.15 | $29,131.80 |
DisclosureSEC source: 0001093557-20-000330 · edgardoc.xml · nonDerivative · entry 7 DOUBLEDAY RICHARD · CIK 0001466545 · EVP Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Indirect · by Trust Disclosed balance after: 9,983 F1 · shares: On June 15, 2020, Mr. Doubleday adopted a 10b5-1 Plan. This 10b5-1 Plan allows the orderly disposition of shares owned by Mr. Doubleday. The shares set forth above were sold pursuant to the 10b5-1 Plan. F9 · price: This transaction was executed in multiple trades at prices ranging from $363.94 to $364.24. The price above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transactions were effected. F3 · ownership.nature: Shares are held by the Doubleday Living Trust U/A/D 5/26/2015, with respect to which the reporting person is a trustee. Read SEC document |
| December 23, 2020 Filed Dec 28, 2020 22:43 UTC | DEXCOM INC DXCM · Entity 3114 | SaleCommon Stock | 60 | $362.83 | $21,770.00 |
DisclosureSEC source: 0001093557-20-000330 · edgardoc.xml · nonDerivative · entry 6 DOUBLEDAY RICHARD · CIK 0001466545 · EVP Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Indirect · by Trust Disclosed balance after: 10,063 F1 · shares: On June 15, 2020, Mr. Doubleday adopted a 10b5-1 Plan. This 10b5-1 Plan allows the orderly disposition of shares owned by Mr. Doubleday. The shares set forth above were sold pursuant to the 10b5-1 Plan. F8 · price: This transaction was executed in multiple trades at prices ranging from $362.50 to $363.00. The price above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transactions were effected. F3 · ownership.nature: Shares are held by the Doubleday Living Trust U/A/D 5/26/2015, with respect to which the reporting person is a trustee. Read SEC document |
| December 23, 2020 Filed Dec 28, 2020 22:43 UTC | DEXCOM INC DXCM · Entity 3114 | SaleCommon Stock | 180 | $361.46 | $65,063.00 |
DisclosureSEC source: 0001093557-20-000330 · edgardoc.xml · nonDerivative · entry 5 DOUBLEDAY RICHARD · CIK 0001466545 · EVP Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Indirect · by Trust Disclosed balance after: 10,123 F1 · shares: On June 15, 2020, Mr. Doubleday adopted a 10b5-1 Plan. This 10b5-1 Plan allows the orderly disposition of shares owned by Mr. Doubleday. The shares set forth above were sold pursuant to the 10b5-1 Plan. F7 · price: This transaction was executed in multiple trades at prices ranging from $361.08 to $361.90. The price above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transactions were effected. F3 · ownership.nature: Shares are held by the Doubleday Living Trust U/A/D 5/26/2015, with respect to which the reporting person is a trustee. Read SEC document |
| December 23, 2020 Filed Dec 28, 2020 22:43 UTC | DEXCOM INC DXCM · Entity 3114 | SaleCommon Stock | 123 | $360.62 | $44,355.89 |
DisclosureSEC source: 0001093557-20-000330 · edgardoc.xml · nonDerivative · entry 4 DOUBLEDAY RICHARD · CIK 0001466545 · EVP Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Indirect · by Trust Disclosed balance after: 10,303 F1 · shares: On June 15, 2020, Mr. Doubleday adopted a 10b5-1 Plan. This 10b5-1 Plan allows the orderly disposition of shares owned by Mr. Doubleday. The shares set forth above were sold pursuant to the 10b5-1 Plan. F6 · price: This transaction was executed in multiple trades at prices ranging from $360.00 to $360.93. The price above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transactions were effected. F3 · ownership.nature: Shares are held by the Doubleday Living Trust U/A/D 5/26/2015, with respect to which the reporting person is a trustee. Read SEC document |
| December 23, 2020 Filed Dec 28, 2020 22:43 UTC | DEXCOM INC DXCM · Entity 3114 | SaleCommon Stock | 282 | $359.29 | $101,319.50 |
DisclosureSEC source: 0001093557-20-000330 · edgardoc.xml · nonDerivative · entry 3 DOUBLEDAY RICHARD · CIK 0001466545 · EVP Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Indirect · by Trust Disclosed balance after: 10,426 F1 · shares: On June 15, 2020, Mr. Doubleday adopted a 10b5-1 Plan. This 10b5-1 Plan allows the orderly disposition of shares owned by Mr. Doubleday. The shares set forth above were sold pursuant to the 10b5-1 Plan. F5 · price: This transaction was executed in multiple trades at prices ranging from $359.00 to $359.99. The price above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transactions were effected. F3 · ownership.nature: Shares are held by the Doubleday Living Trust U/A/D 5/26/2015, with respect to which the reporting person is a trustee. Read SEC document |
| December 23, 2020 Filed Dec 28, 2020 22:43 UTC | DEXCOM INC DXCM · Entity 3114 | SaleCommon Stock | 265 | $358.48 | $94,998.10 |
DisclosureSEC source: 0001093557-20-000330 · edgardoc.xml · nonDerivative · entry 2 DOUBLEDAY RICHARD · CIK 0001466545 · EVP Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Indirect · by Trust Disclosed balance after: 10,708 F1 · shares: On June 15, 2020, Mr. Doubleday adopted a 10b5-1 Plan. This 10b5-1 Plan allows the orderly disposition of shares owned by Mr. Doubleday. The shares set forth above were sold pursuant to the 10b5-1 Plan. F4 · price: This transaction was executed in multiple trades at prices ranging from $358.000 to $358.925. The price above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transactions were effected. F3 · ownership.nature: Shares are held by the Doubleday Living Trust U/A/D 5/26/2015, with respect to which the reporting person is a trustee. Read SEC document |
| December 23, 2020 Filed Dec 28, 2020 22:43 UTC | DEXCOM INC DXCM · Entity 3114 | SaleCommon Stock | 120 | $357.31 | $42,877.64 |
DisclosureSEC source: 0001093557-20-000330 · edgardoc.xml · nonDerivative · entry 1 DOUBLEDAY RICHARD · CIK 0001466545 · EVP Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Indirect · by Trust Disclosed balance after: 10,973 F1 · shares: On June 15, 2020, Mr. Doubleday adopted a 10b5-1 Plan. This 10b5-1 Plan allows the orderly disposition of shares owned by Mr. Doubleday. The shares set forth above were sold pursuant to the 10b5-1 Plan. F2 · price: This transaction was executed in multiple trades at prices ranging from $357.00 to $357.50. The price above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transactions were effected. F3 · ownership.nature: Shares are held by the Doubleday Living Trust U/A/D 5/26/2015, with respect to which the reporting person is a trustee. Read SEC document |
| November 23, 2020 Filed Nov 25, 2020 21:50 UTC | DEXCOM INC DXCM · Entity 3114 | SaleCommon Stock | 1,110 | $318.99 | $354,078.90 |
DisclosureSEC source: 0001093557-20-000317 · edgardoc.xml · nonDerivative · entry 1 DOUBLEDAY RICHARD · CIK 0001466545 · EVP Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Indirect · by Trust Disclosed balance after: 11,093 F1 · shares: On June 15, 2020, Mr. Doubleday adopted a 10b5-1 Plan. This 10b5-1 Plan allows the orderly disposition of shares owned by Mr. Doubleday. The shares set forth above were sold pursuant to the 10b5-1 Plan. F2 · ownership.nature: Shares are held by the Doubleday Living Trust U/A/D 5/26/2015, with respect to which the reporting person is a trustee. Read SEC document |
| October 23, 2020 Filed Oct 27, 2020 22:19 UTC | DEXCOM INC DXCM · Entity 3114 | SaleCommon Stock | 83 | $408.00 | $33,864.00 |
DisclosureSEC source: 0001093557-20-000297 · edgardoc.xml · nonDerivative · entry 10 DOUBLEDAY RICHARD · CIK 0001466545 · EVP Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Indirect · by Trust Disclosed balance after: 12,203 F4 · shares: On June 15, 2020, Mr. Doubleday adopted a 10b5-1 Plan. This 10b5-1 Plan allows the orderly disposition of shares owned by Mr. Doubleday. The shares set forth above were sold pursuant to the 10b5-1 Plan. F3 · ownership.nature: Shares are held by the Doubleday Living Trust U/A/D 5/26/2015, with respect to which the reporting person is a trustee. Read SEC document |
| October 23, 2020 Filed Oct 27, 2020 22:19 UTC | DEXCOM INC DXCM · Entity 3114 | SaleCommon Stock | 68 | $406.93 | $27,671.24 |
DisclosureSEC source: 0001093557-20-000297 · edgardoc.xml · nonDerivative · entry 9 DOUBLEDAY RICHARD · CIK 0001466545 · EVP Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Indirect · by Trust Disclosed balance after: 12,286 F4 · shares: On June 15, 2020, Mr. Doubleday adopted a 10b5-1 Plan. This 10b5-1 Plan allows the orderly disposition of shares owned by Mr. Doubleday. The shares set forth above were sold pursuant to the 10b5-1 Plan. F3 · ownership.nature: Shares are held by the Doubleday Living Trust U/A/D 5/26/2015, with respect to which the reporting person is a trustee. Read SEC document |
| October 23, 2020 Filed Oct 27, 2020 22:19 UTC | DEXCOM INC DXCM · Entity 3114 | SaleCommon Stock | 263 | $406.45 | $106,895.80 |
DisclosureSEC source: 0001093557-20-000297 · edgardoc.xml · nonDerivative · entry 8 DOUBLEDAY RICHARD · CIK 0001466545 · EVP Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Indirect · by Trust Disclosed balance after: 12,354 F4 · shares: On June 15, 2020, Mr. Doubleday adopted a 10b5-1 Plan. This 10b5-1 Plan allows the orderly disposition of shares owned by Mr. Doubleday. The shares set forth above were sold pursuant to the 10b5-1 Plan. F8 · price: This transaction was executed in multiple trades at prices ranging from $405.88 to $406.865. The price above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transactions were effected. F3 · ownership.nature: Shares are held by the Doubleday Living Trust U/A/D 5/26/2015, with respect to which the reporting person is a trustee. Read SEC document |
| October 23, 2020 Filed Oct 27, 2020 22:19 UTC | DEXCOM INC DXCM · Entity 3114 | SaleCommon Stock | 213 | $405.07 | $86,279.80 |
DisclosureSEC source: 0001093557-20-000297 · edgardoc.xml · nonDerivative · entry 7 DOUBLEDAY RICHARD · CIK 0001466545 · EVP Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Indirect · by Trust Disclosed balance after: 12,617 F4 · shares: On June 15, 2020, Mr. Doubleday adopted a 10b5-1 Plan. This 10b5-1 Plan allows the orderly disposition of shares owned by Mr. Doubleday. The shares set forth above were sold pursuant to the 10b5-1 Plan. F7 · price: This transaction was executed in multiple trades at prices ranging from $404.715 to $405.58. The price above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transactions were effected. F3 · ownership.nature: Shares are held by the Doubleday Living Trust U/A/D 5/26/2015, with respect to which the reporting person is a trustee. Read SEC document |
| October 23, 2020 Filed Oct 27, 2020 22:19 UTC | DEXCOM INC DXCM · Entity 3114 | SaleCommon Stock | 6 | $403.49 | $2,420.94 |
DisclosureSEC source: 0001093557-20-000297 · edgardoc.xml · nonDerivative · entry 6 DOUBLEDAY RICHARD · CIK 0001466545 · EVP Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Indirect · by Trust Disclosed balance after: 12,830 F4 · shares: On June 15, 2020, Mr. Doubleday adopted a 10b5-1 Plan. This 10b5-1 Plan allows the orderly disposition of shares owned by Mr. Doubleday. The shares set forth above were sold pursuant to the 10b5-1 Plan. F3 · ownership.nature: Shares are held by the Doubleday Living Trust U/A/D 5/26/2015, with respect to which the reporting person is a trustee. Read SEC document |
| October 23, 2020 Filed Oct 27, 2020 22:19 UTC | DEXCOM INC DXCM · Entity 3114 | SaleCommon Stock | 74 | $402.57 | $29,789.90 |
DisclosureSEC source: 0001093557-20-000297 · edgardoc.xml · nonDerivative · entry 5 DOUBLEDAY RICHARD · CIK 0001466545 · EVP Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Indirect · by Trust Disclosed balance after: 12,836 F4 · shares: On June 15, 2020, Mr. Doubleday adopted a 10b5-1 Plan. This 10b5-1 Plan allows the orderly disposition of shares owned by Mr. Doubleday. The shares set forth above were sold pursuant to the 10b5-1 Plan. F6 · price: This transaction was executed in multiple trades at prices ranging from $401.80 to $402.61. The price above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transactions were effected. F3 · ownership.nature: Shares are held by the Doubleday Living Trust U/A/D 5/26/2015, with respect to which the reporting person is a trustee. Read SEC document |
| October 23, 2020 Filed Oct 27, 2020 22:19 UTC | DEXCOM INC DXCM · Entity 3114 | SaleCommon Stock | 156 | $399.63 | $62,342.28 |
DisclosureSEC source: 0001093557-20-000297 · edgardoc.xml · nonDerivative · entry 4 DOUBLEDAY RICHARD · CIK 0001466545 · EVP Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Indirect · by Trust Disclosed balance after: 12,910 F4 · shares: On June 15, 2020, Mr. Doubleday adopted a 10b5-1 Plan. This 10b5-1 Plan allows the orderly disposition of shares owned by Mr. Doubleday. The shares set forth above were sold pursuant to the 10b5-1 Plan. F3 · ownership.nature: Shares are held by the Doubleday Living Trust U/A/D 5/26/2015, with respect to which the reporting person is a trustee. Read SEC document |
| October 23, 2020 Filed Oct 27, 2020 22:19 UTC | DEXCOM INC DXCM · Entity 3114 | SaleCommon Stock | 247 | $397.49 | $98,180.23 |
DisclosureSEC source: 0001093557-20-000297 · edgardoc.xml · nonDerivative · entry 3 DOUBLEDAY RICHARD · CIK 0001466545 · EVP Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Indirect · by Trust Disclosed balance after: 13,066 F4 · shares: On June 15, 2020, Mr. Doubleday adopted a 10b5-1 Plan. This 10b5-1 Plan allows the orderly disposition of shares owned by Mr. Doubleday. The shares set forth above were sold pursuant to the 10b5-1 Plan. F5 · price: This transaction was executed in multiple trades at prices ranging from $397.025 to $398.00. The price above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transactions were effected. F3 · ownership.nature: Shares are held by the Doubleday Living Trust U/A/D 5/26/2015, with respect to which the reporting person is a trustee. Read SEC document |
| October 14, 2020 Filed Oct 27, 2020 22:19 UTC | DEXCOM INC DXCM · Entity 3114 | OtherCommon Stock | 13,313 | $0.00 | $0.00 |
DisclosureSEC source: 0001093557-20-000297 · edgardoc.xml · nonDerivative · entry 2 DOUBLEDAY RICHARD · CIK 0001466545 · EVP Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Indirect · by Trust Disclosed balance after: 13,313 F1 · shares: Shares were transferred from direct ownership to ownership under the Doubleday Living Trust U/A/D 5/26/2015, with respect to which the reporting person is a trustee. F3 · ownership.nature: Shares are held by the Doubleday Living Trust U/A/D 5/26/2015, with respect to which the reporting person is a trustee. Read SEC document |
| October 14, 2020 Filed Oct 27, 2020 22:19 UTC | DEXCOM INC DXCM · Entity 3114 | OtherCommon Stock | 13,313 | $0.00 | $0.00 |
DisclosureSEC source: 0001093557-20-000297 · edgardoc.xml · nonDerivative · entry 1 DOUBLEDAY RICHARD · CIK 0001466545 · EVP Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 33,499 F1 · shares: Shares were transferred from direct ownership to ownership under the Doubleday Living Trust U/A/D 5/26/2015, with respect to which the reporting person is a trustee. F2 · balance_after: Included in this number are 26,348 unvested restricted stock units, 11,748 of which were granted on March 8, 2020 and shall vest through March 8, 2023, 8,183 of which were granted on March 8, 2019 and shall vest through March 8, 2022 and 6,417 of which were granted on March 8, 2018 and shall vest through March 8, 2021. Read SEC document |
| September 24, 2020 Filed Sep 28, 2020 21:35 UTC | DEXCOM INC DXCM · Entity 3114 | SaleCommon Stock | 1,430 | $381.00 | $544,830.00 |
DisclosureSEC source: 0001093557-20-000271 · edgardoc.xml · nonDerivative · entry 2 DOUBLEDAY RICHARD · CIK 0001466545 · EVP Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Indirect · by Trust Disclosed balance after: 0 F1 · shares: On June 3, 2019, Mr. Doubleday adopted a 10b5-1 Plan. This 10b5-1 Plan allows the orderly disposition of shares owned by Mr. Doubleday. The shares set forth above were sold pursuant to the 10b5-1 Plan. F3 · ownership.nature: Shares are held by the Doubleday Living Trust U/A/D 5/26/2015, with respect to which the reporting person is a trustee. Read SEC document |
| September 24, 2020 Filed Sep 28, 2020 21:35 UTC | DEXCOM INC DXCM · Entity 3114 | SaleCommon Stock | 100 | $380.31 | $38,030.55 |
DisclosureSEC source: 0001093557-20-000271 · edgardoc.xml · nonDerivative · entry 1 DOUBLEDAY RICHARD · CIK 0001466545 · EVP Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Indirect · by Trust Disclosed balance after: 1,430 F1 · shares: On June 3, 2019, Mr. Doubleday adopted a 10b5-1 Plan. This 10b5-1 Plan allows the orderly disposition of shares owned by Mr. Doubleday. The shares set forth above were sold pursuant to the 10b5-1 Plan. F2 · price: This transaction was executed in multiple trades at prices ranging from $380.00 to $380.37. The price above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transactions were effected. F3 · ownership.nature: Shares are held by the Doubleday Living Trust U/A/D 5/26/2015, with respect to which the reporting person is a trustee. Read SEC document |
| September 09, 2020 Filed Sep 11, 2020 22:58 UTC | DEXCOM INC DXCM · Entity 3114 | SaleCommon Stock | 1,402 | $398.30 | $558,419.40 |
DisclosureSEC source: 0001093557-20-000250 · edgardoc.xml · nonDerivative · entry 2 DOUBLEDAY RICHARD · CIK 0001466545 · EVP Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 46,812 F1 · shares: Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of RSUs. This sale is mandated by the Issuer's election under its equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the reporting person. F2 · balance_after: Included in this number are 26,348 unvested restricted stock units, 11,748 of which were granted on March 8, 2020 and shall vest through March 8, 2023, 8,183 of which were granted on March 8, 2019 and shall vest through March 8, 2022 and 6,417 of which were granted on March 8, 2018 and shall vest through March 8, 2021. Read SEC document |
| September 09, 2020 Filed Sep 11, 2020 22:58 UTC | DEXCOM INC DXCM · Entity 3114 | SaleCommon Stock | 3,297 | $398.30 | $1,313,201.69 |
DisclosureSEC source: 0001093557-20-000250 · edgardoc.xml · nonDerivative · entry 1 DOUBLEDAY RICHARD · CIK 0001466545 · EVP Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 48,214 F1 · shares: Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of RSUs. This sale is mandated by the Issuer's election under its equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the reporting person. F2 · balance_after: Included in this number are 26,348 unvested restricted stock units, 11,748 of which were granted on March 8, 2020 and shall vest through March 8, 2023, 8,183 of which were granted on March 8, 2019 and shall vest through March 8, 2022 and 6,417 of which were granted on March 8, 2018 and shall vest through March 8, 2021. Read SEC document |
| August 24, 2020 Filed Aug 26, 2020 23:03 UTC | DEXCOM INC DXCM · Entity 3114 | SaleCommon Stock | 1,530 | $427.22 | $653,642.16 |
DisclosureSEC source: 0001093557-20-000233 · edgardoc.xml · nonDerivative · entry 1 DOUBLEDAY RICHARD · CIK 0001466545 · EVP Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Indirect · by Trust Disclosed balance after: 1,530 F1 · shares: On June 3, 2019, Mr. Doubleday adopted a 10b5-1 Plan. This 10b5-1 Plan allows the orderly disposition of shares owned by Mr. Doubleday. The shares set forth above were sold pursuant to the 10b5-1 Plan. F2 · price: This transaction was executed in multiple trades at prices ranging from $426.46 to $427.41. The price above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transactions were effected. F3 · ownership.nature: Shares are held by the Doubleday Living Trust U/A/D 5/26/2015, with respect to which the reporting person is a trustee. Read SEC document |
| July 23, 2020 Filed Jul 27, 2020 21:53 UTC | DEXCOM INC DXCM · Entity 3114 | SaleCommon Stock | 571 | $429.60 | $245,302.68 |
DisclosureSEC source: 0001093557-20-000209 · edgardoc.xml · nonDerivative · entry 6 DOUBLEDAY RICHARD · CIK 0001466545 · EVP Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Indirect · by Trust Disclosed balance after: 3,060 F1 · shares: On June 3, 2019, Mr. Doubleday adopted a 10b5-1 Plan. This 10b5-1 Plan allows the orderly disposition of shares owned by Mr. Doubleday. The shares set forth above were sold pursuant to the 10b5-1 Plan. F5 · price: This transaction was executed in multiple trades at prices ranging from $429.38 to $429.82. The price above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transactions were effected. F2 · ownership.nature: Shares are held by the Doubleday Living Trust U/A/D 5/26/2015, with respect to which the reporting person is a trustee. Read SEC document |
| July 23, 2020 Filed Jul 27, 2020 21:53 UTC | DEXCOM INC DXCM · Entity 3114 | SaleCommon Stock | 107 | $428.52 | $45,851.25 |
DisclosureSEC source: 0001093557-20-000209 · edgardoc.xml · nonDerivative · entry 5 DOUBLEDAY RICHARD · CIK 0001466545 · EVP Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Indirect · by Trust Disclosed balance after: 3,631 F1 · shares: On June 3, 2019, Mr. Doubleday adopted a 10b5-1 Plan. This 10b5-1 Plan allows the orderly disposition of shares owned by Mr. Doubleday. The shares set forth above were sold pursuant to the 10b5-1 Plan. F4 · price: This transaction was executed in multiple trades at prices ranging from $428.24 to $428.82. The price above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transactions were effected. F2 · ownership.nature: Shares are held by the Doubleday Living Trust U/A/D 5/26/2015, with respect to which the reporting person is a trustee. Read SEC document |
| July 23, 2020 Filed Jul 27, 2020 21:53 UTC | DEXCOM INC DXCM · Entity 3114 | SaleCommon Stock | 476 | $427.36 | $203,423.36 |
DisclosureSEC source: 0001093557-20-000209 · edgardoc.xml · nonDerivative · entry 4 DOUBLEDAY RICHARD · CIK 0001466545 · EVP Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Indirect · by Trust Disclosed balance after: 3,738 F1 · shares: On June 3, 2019, Mr. Doubleday adopted a 10b5-1 Plan. This 10b5-1 Plan allows the orderly disposition of shares owned by Mr. Doubleday. The shares set forth above were sold pursuant to the 10b5-1 Plan. F3 · price: This transaction was executed in multiple trades at prices ranging from $427.20 to $428.13. The price above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transactions were effected. F2 · ownership.nature: Shares are held by the Doubleday Living Trust U/A/D 5/26/2015, with respect to which the reporting person is a trustee. Read SEC document |
| July 23, 2020 Filed Jul 27, 2020 21:53 UTC | DEXCOM INC DXCM · Entity 3114 | SaleCommon Stock | 94 | $425.99 | $40,043.06 |
DisclosureSEC source: 0001093557-20-000209 · edgardoc.xml · nonDerivative · entry 3 DOUBLEDAY RICHARD · CIK 0001466545 · EVP Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Indirect · by Trust Disclosed balance after: 4,214 F1 · shares: On June 3, 2019, Mr. Doubleday adopted a 10b5-1 Plan. This 10b5-1 Plan allows the orderly disposition of shares owned by Mr. Doubleday. The shares set forth above were sold pursuant to the 10b5-1 Plan. F2 · ownership.nature: Shares are held by the Doubleday Living Trust U/A/D 5/26/2015, with respect to which the reporting person is a trustee. Read SEC document |
| July 23, 2020 Filed Jul 27, 2020 21:53 UTC | DEXCOM INC DXCM · Entity 3114 | SaleCommon Stock | 83 | $424.63 | $35,244.29 |
DisclosureSEC source: 0001093557-20-000209 · edgardoc.xml · nonDerivative · entry 2 DOUBLEDAY RICHARD · CIK 0001466545 · EVP Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Indirect · by Trust Disclosed balance after: 4,308 F1 · shares: On June 3, 2019, Mr. Doubleday adopted a 10b5-1 Plan. This 10b5-1 Plan allows the orderly disposition of shares owned by Mr. Doubleday. The shares set forth above were sold pursuant to the 10b5-1 Plan. F2 · ownership.nature: Shares are held by the Doubleday Living Trust U/A/D 5/26/2015, with respect to which the reporting person is a trustee. Read SEC document |
| July 23, 2020 Filed Jul 27, 2020 21:53 UTC | DEXCOM INC DXCM · Entity 3114 | SaleCommon Stock | 200 | $421.62 | $84,323.00 |
DisclosureSEC source: 0001093557-20-000209 · edgardoc.xml · nonDerivative · entry 1 DOUBLEDAY RICHARD · CIK 0001466545 · EVP Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Indirect · by Trust Disclosed balance after: 4,391 F1 · shares: On June 3, 2019, Mr. Doubleday adopted a 10b5-1 Plan. This 10b5-1 Plan allows the orderly disposition of shares owned by Mr. Doubleday. The shares set forth above were sold pursuant to the 10b5-1 Plan. F2 · ownership.nature: Shares are held by the Doubleday Living Trust U/A/D 5/26/2015, with respect to which the reporting person is a trustee. Read SEC document |
| June 23, 2020 Filed Jun 25, 2020 22:45 UTC | DEXCOM INC DXCM · Entity 3114 | SaleCommon Stock | 227 | $411.54 | $93,419.04 |
DisclosureSEC source: 0001093557-20-000196 · edgardoc.xml · nonDerivative · entry 4 DOUBLEDAY RICHARD · CIK 0001466545 · EVP Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Indirect · by Trust Disclosed balance after: 4,591 F1 · shares: On June 3, 2019, Mr. Doubleday adopted a 10b5-1 Plan. This 10b5-1 Plan allows the orderly disposition of shares owned by Mr. Doubleday. The shares set forth above were sold pursuant to the 10b5-1 Plan. F6 · price: This transaction was executed in multiple trades at prices ranging from $411.02 to $411.96. The price above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transactions were effected. F3 · ownership.nature: Shares are held by the Doubleday Living Trust U/A/D 5/26/2015, with respect to which the reporting person is a trustee. Read SEC document |
| June 23, 2020 Filed Jun 25, 2020 22:45 UTC | DEXCOM INC DXCM · Entity 3114 | SaleCommon Stock | 595 | $410.26 | $244,106.60 |
DisclosureSEC source: 0001093557-20-000196 · edgardoc.xml · nonDerivative · entry 3 DOUBLEDAY RICHARD · CIK 0001466545 · EVP Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Indirect · by Trust Disclosed balance after: 4,818 F1 · shares: On June 3, 2019, Mr. Doubleday adopted a 10b5-1 Plan. This 10b5-1 Plan allows the orderly disposition of shares owned by Mr. Doubleday. The shares set forth above were sold pursuant to the 10b5-1 Plan. F5 · price: This transaction was executed in multiple trades at prices ranging from $409.88 to $410.74. The price above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transactions were effected. F3 · ownership.nature: Shares are held by the Doubleday Living Trust U/A/D 5/26/2015, with respect to which the reporting person is a trustee. Read SEC document |
| June 23, 2020 Filed Jun 25, 2020 22:45 UTC | DEXCOM INC DXCM · Entity 3114 | SaleCommon Stock | 354 | $408.90 | $144,750.21 |
DisclosureSEC source: 0001093557-20-000196 · edgardoc.xml · nonDerivative · entry 2 DOUBLEDAY RICHARD · CIK 0001466545 · EVP Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Indirect · by Trust Disclosed balance after: 5,413 F1 · shares: On June 3, 2019, Mr. Doubleday adopted a 10b5-1 Plan. This 10b5-1 Plan allows the orderly disposition of shares owned by Mr. Doubleday. The shares set forth above were sold pursuant to the 10b5-1 Plan. F4 · price: This transaction was executed in multiple trades at prices ranging from $408.73 to $409.25. The price above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transactions were effected. F3 · ownership.nature: Shares are held by the Doubleday Living Trust U/A/D 5/26/2015, with respect to which the reporting person is a trustee. Read SEC document |
| June 23, 2020 Filed Jun 25, 2020 22:45 UTC | DEXCOM INC DXCM · Entity 3114 | SaleCommon Stock | 355 | $407.13 | $144,531.33 |
DisclosureSEC source: 0001093557-20-000196 · edgardoc.xml · nonDerivative · entry 1 DOUBLEDAY RICHARD · CIK 0001466545 · EVP Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Indirect · by Trust Disclosed balance after: 5,767 F1 · shares: On June 3, 2019, Mr. Doubleday adopted a 10b5-1 Plan. This 10b5-1 Plan allows the orderly disposition of shares owned by Mr. Doubleday. The shares set forth above were sold pursuant to the 10b5-1 Plan. F2 · price: This transaction was executed in multiple trades at prices ranging from $406.99 to $407.37. The price above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transactions were effected. F3 · ownership.nature: Shares are held by the Doubleday Living Trust U/A/D 5/26/2015, with respect to which the reporting person is a trustee. Read SEC document |
| May 22, 2020 Filed May 27, 2020 21:56 UTC | DEXCOM INC DXCM · Entity 3114 | SaleCommon Stock | 1,531 | $396.74 | $607,408.94 |
DisclosureSEC source: 0001093557-20-000170 · edgardoc.xml · nonDerivative · entry 1 DOUBLEDAY RICHARD · CIK 0001466545 · EVP Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Indirect · by Trust Disclosed balance after: 6,122 F1 · shares: On June 3, 2019, Mr. Doubleday adopted a 10b5-1 Plan. This 10b5-1 Plan allows the orderly disposition of shares owned by Mr. Doubleday. The shares set forth above were sold pursuant to the 10b5-1 Plan. F2 · ownership.nature: Shares are held by the Doubleday Living Trust U/A/D 5/26/2015, with respect to which the reporting person is a trustee. Read SEC document |
| April 23, 2020 Filed Apr 27, 2020 21:00 UTC | DEXCOM INC DXCM · Entity 3114 | SaleCommon Stock | 1,530 | $318.57 | $487,412.10 |
DisclosureSEC source: 0001093557-20-000134 · edgardoc.xml · nonDerivative · entry 1 DOUBLEDAY RICHARD · CIK 0001466545 · EVP Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Indirect · by Trust Disclosed balance after: 7,653 F1 · shares: On June 3, 2019, Mr. Doubleday adopted a 10b5-1 Plan. This 10b5-1 Plan allows the orderly disposition of shares owned by Mr. Doubleday. The shares set forth above were sold pursuant to the 10b5-1 Plan. F2 · ownership.nature: Shares are held by the Doubleday Living Trust U/A/D 5/26/2015, with respect to which the reporting person is a trustee. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.